Patents by Inventor Jason Cameron

Jason Cameron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220228677
    Abstract: A method of securing a pipe in a hanger includes supporting the pipe with a suspension member; inserting a threaded rod through the suspension member; placing a lock tab washer on the threaded rod; threading a nut on the threaded rod; preventing the lock tab washer from rotating with respect to the suspension member by folding a first tab of the lock tab washer over a side edge of the suspension member; and preventing the nut from rotating with respect to the lock tab washer by folding a second tab of the lock tab washer over a circumferential side of the nut.
    Type: Application
    Filed: April 4, 2022
    Publication date: July 21, 2022
    Inventors: Jordan Cameron Belen, Matthew William McNamara, Jason F. Santos
  • Publication number: 20210333279
    Abstract: In a first aspect, the invention relates to the identification of cancer types over-expressing the FcRn receptor. In a second aspect, the invention relates to the treatment of said cancer types. In further aspects, the invention relates to identification of subtypes of inflammatory diseases and treatments thereof. In an additional aspect, the invention relates to in vivo imaging of cancers over-expressing the FcRn receptor.
    Type: Application
    Filed: November 3, 2017
    Publication date: October 28, 2021
    Inventors: Kenneth Alan Howard, Jason Cameron, Maja Thim Larsen, Frederik Dagnæs-Hansen
  • Patent number: 10934341
    Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: March 2, 2021
    Assignee: ALBUMEDIX, LTD.
    Inventors: Jason Cameron, Karen Ann Delahay, Jens Erik Nielsen, Andrew Plumridge, Jan Terje Andersen
  • Publication number: 20200392206
    Abstract: Based on the three-dimensional structure of albumin, the inventors have designed variant polypeptides (muteins) which have one or more cysteine residues with a free thiol group (hereinafter referred to as “thio-albumin”). The variant polypeptide may be conjugated through the sulphur atom of the cysteine residue to a conjugation partner such as a bioactive compound.
    Type: Application
    Filed: March 23, 2020
    Publication date: December 17, 2020
    Inventors: Christopher John Arthur Finnis, Joanna Mary Hay, Esben Peter Friis, Jason Cameron, Darrell Sleep
  • Publication number: 20200385442
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: May 22, 2020
    Publication date: December 10, 2020
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Patent number: 10696732
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: June 30, 2020
    Assignee: ALBUMEDIX, LTD
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20200102368
    Abstract: The invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: October 22, 2019
    Publication date: April 2, 2020
    Inventors: Jan Terje Andersen, Bjorn Dalhus, Inger Sandlie, Jason Cameron, Andrew Plumridge, Esben Peter Friis, Karen Ann Delahay
  • Publication number: 20200102367
    Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: October 10, 2019
    Publication date: April 2, 2020
    Inventors: Jason Cameron, Karen Ann Delahay, Jens Erik Nielsen, Andrew Plumridge, Jan Terje Andersen
  • Patent number: 10501524
    Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: December 10, 2019
    Assignee: ALBUMEDIX LTD
    Inventors: Jason Cameron, Karen Ann Delahay, Jens Erik Nielsen, Andrew Plumridge, Jan Terje Andersen
  • Publication number: 20190113519
    Abstract: The present invention relates to a method of assessing pharmacokinetic properties of a variant of human serum albumin using a non-primate animal species where the native albumin of the animal provides minimal competition for HSA binding to the FcRn receptor in said animal. In the non-primate animal species, the binding affinity of wild type HSA to the native FcRn of said animal is the same as or higher than the binding affinity of the native albumin of said animal to the native FcRn. The present invention also relate to animal models which are particularly suitable for assessing pharmacokinetics of human serum albumin variants.
    Type: Application
    Filed: May 7, 2018
    Publication date: April 18, 2019
    Inventors: Jason Cameron, Darrell Sleep, Jan Terje Andersen, Inger Sandlie
  • Patent number: 10233228
    Abstract: The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: March 19, 2019
    Assignee: ALBUMEDIX LTD
    Inventors: Andrew Plumridge, Darrell Sleep, Inger Sandlie, Jan Terje Andersen, Jason Cameron, Leslie Evans, Steven Athwal, Elizabeth Allan, Esben Peter Friis
  • Publication number: 20180265570
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: May 14, 2018
    Publication date: September 20, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180222963
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: January 12, 2018
    Publication date: August 9, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180162925
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: January 12, 2018
    Publication date: June 14, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180105578
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 19, 2017
    Publication date: April 19, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180105576
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 19, 2017
    Publication date: April 19, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180105577
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 19, 2017
    Publication date: April 19, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20180072792
    Abstract: The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
    Type: Application
    Filed: September 19, 2017
    Publication date: March 15, 2018
    Inventors: Darrell Sleep, Andrew Plumridge, Jason Cameron, Inger Sandlie, Jan Terje Andersen, Esben Peter Friis
  • Publication number: 20170081389
    Abstract: Based on the three-dimensional structure of albumin, the inventors have designed variant polypeptides (muteins) which have one or more cysteine residues with a free thiol group (hereinafter referred to as “thio-albumin”). The variant polypeptide may be conjugated through the sulphur atom of the cysteine residue to a conjugation partner such as a bioactive compound.
    Type: Application
    Filed: September 29, 2016
    Publication date: March 23, 2017
    Inventors: Christopher John Arthur Finnis, Joanna Mary Hay, Esben Peter Friis, Jason Cameron, Darrell Sleep
  • Publication number: 20160222087
    Abstract: The present invention relates to variants of a parent albumin; the variants comprise one or more mutations in Domain II of albumin which lead to a change in binding affinity to FcRn and/or a change in half-life compared to the “parent” albumin. The invention allows tailoring of binding affinity and/or half-life of an albumin to the requirements and desires of a user or application. The invention also relates to fragments and fusion polypeptide of the variant albumins, as well as to polynucleotides encoding the variants, nucleic acid constructs, vectors, host cells comprising the polynucleotides and methods of using said variants.
    Type: Application
    Filed: September 12, 2014
    Publication date: August 4, 2016
    Applicant: Novozymes Biopharma DK A/S
    Inventors: Karen DELAHAY, Jason CAMERON